---
title: A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
nct_id: NCT05367700
overall_status: RECRUITING
phase: PHASE1
sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
study_type: INTERVENTIONAL
primary_condition: CML, Chronic Phase
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05367700.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05367700"
ct_last_update_post_date: 2023-01-13
last_seen_at: "2026-05-12T06:32:15.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

**Official Title:** A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Single and Multiple Doses of Oral Administration of HS-10382 in Patients With Chronic Myeloid Leukemia.

**NCT ID:** [NCT05367700](https://clinicaltrials.gov/study/NCT05367700)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 108
- **Lead Sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Conditions:** CML, Chronic Phase, CML, Accelerated Phase
- **Start Date:** 2022-04-28
- **Completion Date:** 2026-09-30
- **CT.gov Last Update:** 2023-01-13

## Brief Summary

HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.

## Detailed Description

This is an open-label, multicenter, dose-escalation and expansion, first-in-human study in participants of CML with T315I mutation or without T315I mutation in chronic phase/accelerate phase(CP/AP). This study will consist of two parts: A part 1 dose escalation stage and a part 2 dose expansion stage. The objectives of this study are to evaluate the safety, tolerability, PK and preliminary anti-CML activity, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum applicable dose (MAD) of HS-10382. Participants with CML-CP/AP are eligible for dose escalation study if they had resistance to or unacceptable side effect from BCR-ABL1 TKIs. After determination of the MTD or the MAD for CML patients, dose expansion will be undertaken to further evaluate the efficacy and safety of HS-10382 in patients with CML-CP. All patients will be carefully followed for adverse events during the study treatment and for 28 days after the last dose of study drug. Subjects of this study will be permitted to continue therapy with assessments for progression if the product is well tolerated and the subject has stable disease or better.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 74 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Signed informed consent form.
2. Men or women aged more than or equal to (≥) 18 years, and less than (\<) 75 years.
3. CML-CP/AP patients with the Ph chromosome or BCR-ABL1 fusion genes.
4. Patient with CML-CP/AP who are resistant to or intolerant to previous TKIs therapy.
5. ECOG performance status of 0-2.
6. Life expectancy ≥ 12 weeks.
7. Men or women should be using adequate contraceptive measures throughout the study; Females should not be breastfeeding at the time of screening, during the study and until 6 months after completion of the study.
8. Females must have evidence of non-childbearing potential.

Exclusion Criteria:

1. CML-CP patients who have acquired CCyR and have not lost it.
2. Patients with CML-CP who have progressed to AP or blast phase(BP.)
3. Patients with CML-AP who have obtained CHR or no evidence of CML in peripheral blood.
4. Patients with CML-AP who have progressed to BP.
5. Previous treatment with a BCR-ABL1 TKI allosteric inhibitor .
6. Impaired cardiac function including any one of the following:

   1. Resting corrected QT interval (QTc) \> 470 ms obtained from electrocardiogram (ECG), using the screening clinic's ECG machine and Fridericia's formula for QT interval correction (QTcF).
   2. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG.
   3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events,
   4. Left ventricular ejection fraction (LVEF) ≤ 50%.
   5. During screening period, ECG examination showed average heart rate \<50 beats per minute.
   6. Myocardial infarction occurred within 6 months of the first scheduled dose of HS-10382.;
   7. Congestive heart failure occurred within 6 months of the first scheduled dose of HS-10382.;
   8. Uncontrollable angina.
7. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
8. Any severe or uncontrolled systemic diseases (i.e. uncontrolled hypertension or diabetes).
9. Clinically severe gastrointestinal dysfunction that may affect drug intake, transport or absorption.
10. Severe infection within 4 weeks prior to the first scheduled dose of HS-10382.
11. History of significant congenital or acquired bleeding disorders unrelated to CML.
12. Inadequate other organ function.
13. History of other malignancies.
14. History of hypersensitivity to any active or inactive ingredient of HS-10382.
15. History of neuropathy or mental disorders, including epilepsy and dementia.
16. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
```

## Arms

- **HS-10382 (Part 1: Dose escalation)** (EXPERIMENTAL) — There are five escalation dose cohorts.
- **HS-10382 (Part 2: Dose expansion)** (EXPERIMENTAL) — The recommended dose from the dose-escalation stage and other potential doses will be further explored.

## Interventions

- **HS-10382(Part 1: Dose escalation)** (DRUG) — Single or multiple dose(s) of HS-10382 once daily.
- **HS-10382(Part 2: Dose expansion)** (DRUG) — HS-10382 is administered orally once daily.

## Primary Outcomes

- **Part 1(Dose escalation): Maximum tolerated dose (MTD) for HS-10382** _(time frame: From the single dose to the last dose of the first cycle as 28days of multiple dosing (35days).)_ — MTD was defined as the previous dose level at which 2 out of 3 subjects or 2 out of 6 subjects experienced a DLT.
- **Part 2(Dose expansion): Major cytogenetic response (MCyR) rate at 6 months** _(time frame: 6 months)_ — MCyR is the proportion of patients achieving Complete cytogenetic response (CCyR: defined as 0% Philadelphia chromosome-positive \[Ph+\] metaphases by cytogenetic analysis of bone marrow) and Partial Cytogenetic Response (PCyR: defined as \>0% to 35% Ph+ metaphases by cytogenetic analysis of bone marrow).

## Secondary Outcomes

- **Incidence and severity of treatment-emergent adverse events** _(time frame: From baseline until 28 days after the last dose.)_
- **Observed maximum plasma concentration (Cmax) after single dose of HS-10382** _(time frame: In the study of single-dose, Cmax will be obtained following administration of a single oral dose of HS-10382 on Day 1 to Day 6.)_
- **Time to reach maximum plasma concentration (Tmax) after single dose of HS-10382** _(time frame: From pre-dose to 120 hours after single dose on Day 1)_
- **Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) after single dose of HS-10382** _(time frame: From pre-dose to 120 hours after single dose on Day 1)_
- **Hematologic response** _(time frame: at screening and 28th day of cycle 1,2,3,4,5,6,9 and 12.)_
- **Molecular response** _(time frame: at screening and 28th day of cycle 3, 6, 9 and 12.)_
- **Cytogenetic response** _(time frame: at screening and 28th day of cycle 3, 6, 9 and 12.)_
- **Event-free survival (EFS)** _(time frame: up to 24 months)_
- **Progression-free survival (PFS)** _(time frame: up to 24 months)_
- **Overall survival (OS)** _(time frame: up to 24 months)_

## Locations (1)

- Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.union hospital affiliated to tongji medical college of huazhong university of science and technology|wuhan|hubei|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05367700.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05367700*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*